Skip to content
Austin Top 50
Author:
Helus Pharma
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
July 21, 2026
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
June 25, 2026
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
June 24, 2026
Helus Pharma™ Announces US$50 Million Underwritten Offering
June 24, 2026
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
June 11, 2026
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
June 1, 2026
Assouline Launches Culture Lounge, a Podcast Convening the Voices Shaping How We Live, Travel, Create, and Collect
May 3, 2026
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
April 30, 2026
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
April 23, 2026
Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer
April 20, 2026
1
2
Next Page
→